Coave Therapeutics will present at Cell & Gene Meeting on the Mediterranean
PARIS, April 13, 2022 /PRNewswire/ — Coave Therapeutics (“Coave”), a clinical-stage biotechnology company focused on developing breakthrough gene therapies for rare diseases of the eye and CNS (central nervous system), today announced that the CEO Rodolphe Clerval will present a company presentation at the Cell & Gene Meeting on the Mediterranean, in Barcelona, Spain to 1:45 p.m. CET the 20and April.
The conference, which runs from 20and at 22n/a April 2022is a hybrid event and the company presentation will be streamed live for virtual attendees.
A recording of the presentation will be available on the virtual platform within 24 hours for on-demand viewing.
About Coave Therapeutics
Coave Therapeutics is a clinical-stage biotechnology company focused on the development of life-changing gene therapies for rare eye and CNS (central nervous system) diseases.
Coave Therapeutics’ next-generation AAV-Ligand conjugate (“ALIGATER”) platform enables targeted delivery and enhanced gene transduction to improve the efficacy of advanced gene therapies for rare diseases.
The Company is advancing a pipeline of novel therapies targeting rare eye and brain diseases where targeted gene therapy using AAV-Ligand has the potential to be most effective.
Coave Therapeutics, headquartered in Paris, France)is backed by leading international strategic and life sciences investors Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé/Turenne.
Sylvie Berrebi, Eleanor Perkin, swallow mark
Tel: +44 (0)7714 306525